engleski

Review of importance specific biomarkers in laboratory medicine for patients who suffer from rheumatic arthritis

Rheumatic arthritis (RA) is the most prominent systemic, chronic, progressive, the autoimmune rheumatic disease in which the immune system attacks cartilage tissue and bones, and sometimes internal organs. It is more common in women than in men. Based on the concentration of anti-carbamylate protein, it can be predicted how much the patient's joints are affected by the autoimmune disease. The results showed that MMP (matrix metalloproteinase) and YKL-40 (heparin glycoprotein and chitin) are important markers for predicting joint failure. MMP3 is significantly associated with disease activity, inflammatory mediators and cartilage breakdown, and is a potential biomarker of disease severity. Immunocytochemical study found that YKL-40 is present in polymorphonuclear cells in the synovial fluid of RA patients. The big correlation is that biomarkers will effectively and safely achieve results on the characteristics of the patient's disease and the treatment group being tested. The future tends to characterize individual profiles, therefore, with the help of genomics and proteomics, significant improvements are expected at the time of diagnosis and response to therapy.

RA (rheumatoid arthritis), biomarkers, YKL-40

nije evidentirano